1. Home
  2. HAVA vs GALT Comparison

HAVA vs GALT Comparison

Compare HAVA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HAVA

Harvard Ave Acquisition Corporation Class A Ordinary Share

N/A

Current Price

$9.99

Market Cap

206.9M

Sector

N/A

ML Signal

N/A

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$3.12

Market Cap

176.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAVA
GALT
Founded
2024
2000
Country
South Korea
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
206.9M
176.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
HAVA
GALT
Price
$9.99
$3.12
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.50
AVG Volume (30 Days)
144.0K
242.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$1.15
52 Week High
$10.01
$7.13

Technical Indicators

Market Signals
Indicator
HAVA
GALT
Relative Strength Index (RSI) 58.00 51.18
Support Level $9.94 $2.90
Resistance Level $10.01 $3.27
Average True Range (ATR) 0.01 0.19
MACD -0.00 0.06
Stochastic Oscillator 49.75 73.57

Price Performance

Historical Comparison
HAVA
GALT

About HAVA Harvard Ave Acquisition Corporation Class A Ordinary Share

Harvard Ave Acquisition Corp is a blank check company.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: